Natco a safer bet in volatile pharma pack

US sales are being driven by niche complex products, domestic specialty range is also seeing traction

The Natco Pharma stock has been among the few outperformers from the pharma pack and given the recent news flow and the company’s growth prospects, there could be more gains for investors.

While Natco launched the Hepatitis-B drug in India on Tuesday, it approved the closure of its qualified institutional placement (QIP) document over the last weekend. But, most significant is last week’s news of Teva dropping patent litigation against Mylan (Natco’s marketing partner) with respect to the US launch of generics of Copaxone 40 mg injections.

Thus the Copaxone 40 mg generic should drive Natco’s fortunes given its potential opportunity of